Alphabet Stock Is Incredibly Undervalued Today
*Stock prices used were end-of-day prices of April 26, 2025. The video was published on April 28, 2025.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Should you invest $1,000 in Alphabet right now?
Before you buy stock in Alphabet, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $680,390!*
Now, it's worth noting Stock Advisor 's total average return is872% — a market-crushing outperformance compared to160%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of April 28, 2025
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Travis Hoium has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, Apple, Microsoft, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Google settles YouTube children's privacy lawsuit
A woman walks by a giant screen with a logo at an event at the Paris Google Lab on the sidelines of the AI Action Summit in Paris, on Feb. 9, 2025. (AP Photo/Thibault Camus,File) Google will pay US$30 million to settle a lawsuit claiming it violated the privacy of children using YouTube by collecting their personal information without parental consent, and using it to send targeted ads. A preliminary settlement of the proposed class action was filed on Monday night in San Jose, California, federal court, and requires approval by U.S. Magistrate Judge Susan van Keulen. Google denied wrongdoing in agreeing to settle. The Alphabet unit agreed in 2019 to pay $170 million in fines and change some practices to settle similar charges by the U.S. Federal Trade Commission and New York Attorney General Letitia James. Some critics viewed that accord as too lenient. Google did not immediately respond to requests for comment on Tuesday. Lawyers for the plaintiffs did not immediately respond to similar requests. The parents or guardians of 34 children accused Google of violating dozens of state laws by letting content providers bait children with cartoons, nursery rhymes and other content to help it collect personal information, even after the 2019 settlement. Van Keulen dismissed claims against the content providers -including Hasbro, Mattel, Cartoon Network and DreamWorks Animation - in January, citing a lack of evidence tying them to Google's alleged data collection. Mediation began the next month, leading to the settlement. The proposed class covers U.S. children under 13 who watched YouTube between July 1, 2013 and April 1, 2020. Lawyers for the plaintiffs said there could be 35 million to 45 million class members. They said if 1% to 2% submit claims, a rate comparable to similar earlier cases, claimants could receive $30 to $60 each, before deducting legal fees and costs. The lawyers plan to seek up to $9 million from the settlement for legal fees. Alphabet posted net income of $62.7 billion on revenue of $186.7 billion in the first half of 2025. The case is C.H. et al v Google LLC et al, U.S. District Court, Northern District of California, No. 19-07016. (Reporting by Jonathan Stempel in New York; Editing by Richard Chang)
Globe and Mail
an hour ago
- Globe and Mail
Palantir Stock's Valuation: Overstretched or Rightfully Earned?
Palantir Technologies PLTR has emerged as one of the most talked-about names in the S&P 500, and not just for what it does, but for what investors are willing to pay for it. With a market capitalization of $420 billion, it now surpasses giants like Coca-Cola and Bank of America. Yet, when viewed through a valuation lens, Palantir stands alone in its league. Its trailing 12-month price-to-earnings ratio exceeds 580X, and its forward 12-month multiple hovers above 225X. Even more striking is its enterprise value relative to forward 12-month revenues of more than 82X, a level rarely seen, even during the most exuberant periods in market history. By that metric, Palantir looks far more expensive than nearly every other established U.S. stock over the past two decades. Such elevated valuations raise the bar for future performance. For a company trading at these levels, expectations around revenue acceleration, margin expansion and long-term scalability must not only be met, but also exceeded. Even minor disappointments can trigger sharp corrections as multiples revert toward historical norms. Companies in the past that reached these kinds of revenue multiples — often 30x or higher — eventually faced tough questions about sustainability. Optimism alone is rarely sufficient when fundamentals lag. That said, Palantir's expanding government and commercial contracts, its robust and evolving AI platforms, and consistent execution lend credibility to its premium valuation. While risks remain, we view Palantir as one of the most compelling long-term AI plays available today. PLTR's Price Performance, Estimates The stock has surged a whopping 130% year to date, significantly outperforming the industry 's 23% rally. The Zacks Consensus Estimate for PLTR's earnings has increased 21.4% over the past 30 days. PLTR stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Stable Defense Alternatives to Palantir As PLTR's valuation moves higher, Lockheed Martin LMT and RTX Corporation RTX offer more grounded defense exposure. Lockheed Martin, with its massive defense contracts, provides steady cash flow and less volatility than PLTR. Its trailing 12-month price-to-earnings ratio is below 25X, and its forward 12-month multiple is just above 16X. Lockheed Martin continues to benefit from global rearmament while trading at modest earnings multiples. Similarly, RTX shines through missile systems. RTX's defense backlog, like LMT's, underscores its stability. Its trailing 12-month price-to-earnings ratio is below 34X and its forward 12-month multiple is just above 24X. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report RTX Corporation (RTX): Free Stock Analysis Report Palantir Technologies Inc. (PLTR): Free Stock Analysis Report
Globe and Mail
2 hours ago
- Globe and Mail
Nutriband (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
Nutriband (NASDAQ: NTRB) announced it will participate in the Emerging Growth Conference on August 20, 2025. Chairman Serguei Melnik will deliver a live, interactive presentation and may open the floor for real-time questions from shareholders and the investment community. To view the full article, visit About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas 512.354.7000 Office Editor@ BioMedWire is powered by IBN
